SOPHiA GENETICS Q3 Revenue Rises 25% as Adjusted EBITDA Loss Narrows
SOPHiA GENETICS reported its third-quarter results on November 3, 2026: revenue rose 25% year over year to $24.3 million, while its adjusted EBITDA loss, a company measure excluding depreciation, amortization, interest, taxes and other specified items, narrowed 31% to $6.1…
Ultima Genomics Wins Sequencing Role in Singapore Program
Ultima Genomics announced on November 2, 2026 that its UG200 Sequencing Platform had been selected for SG-INSIGHT, a cohort under Phase III of Singapore’s National Precision Medicine (NPM) program, through a consortium led by Singapore-based clinical laboratory Lucence with QIAGEN.…
Illumina Raises 2026 Guidance as Q3 Revenue Climbs to $1.13 Billion
Illumina on October 29, 2026, reported revenue of $1.13 billion for the third quarter of fiscal 2026, up 4.2% from $1,084 million a year earlier, and raised its full-year revenue and earnings guidance. The company reported GAAP diluted earnings per…
Tempus xR RNA Sequencing Assay Receives EU IVDR Class C Certification
Tempus AI said in an October 26, 2026 announcement that its xR RNA-sequencing assay has received certification under the European Union’s In Vitro Diagnostic Regulation as a Class C in vitro diagnostic device. The Chicago-based company said the certification covers…
Thermo Fisher Q3 Revenue Rises 9% as Adjusted EPS Gains 15%
Thermo Fisher Scientific on October 21, 2026, reported financial results for the third quarter ended September 26, 2026, with revenue rising 9% to $12.14 billion from $11.12 billion in the same quarter of 2025. GAAP diluted earnings per share grew…
Adaptive Biotechnologies Sets November 4 Date for Q3 2026 Results
Adaptive Biotechnologies will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026, the company said in an October 14 announcement. Company management will webcast a corresponding conference call beginning at 1:30 p.m.…
Guardant360 CDx Gains CE Mark as Camizestrant Companion Diagnostic
Guardant Health announced on October 8, 2026 that its Guardant360 CDx test received CE-marking under Europe’s In Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast…
Tempus Expands Multi-Year Moderna-Merck Collaboration on Intismeran
Tempus announced on October 7, 2026, an expanded, multi-year collaboration with Moderna and Merck, known as MSD outside the United States and Canada, to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an investigational mRNA-based individualized neoantigen therapy being evaluated…
Tempus and Recursion Extend Data Partnership Through November 2029
Tempus AI, Inc. announced on September 21, 2026 that it has extended its data license agreement with Recursion Pharmaceuticals, Inc. through November 2029, and that the two companies have entered into a separate agreement under which Tempus will license Recursion’s…
Adaptive Highlights NCCN Myeloma Guideline Updates Naming clonoSEQ
Adaptive Biotechnologies Corporation announced on September 17, 2026, that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Multiple Myeloma, adding for the first time a dedicated page outlining principles of minimal residual disease…
EviCore to Cover Guardant Health Shield Colorectal Cancer Blood Test
In a September 14, 2026 announcement, Guardant Health said its Shield blood test for colorectal cancer screening will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per American Cancer Society guidelines. The Palo Alto, California-based precision…
Tempus Wins Up to $9.5 Million ARPA-H Award for Heart Failure AI Agent
Tempus AI, Inc. announced on September 9, 2026 that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to receive an award of up to…
Guardant360 CDx Wins FDA Nod as Companion Diagnostic for Camizestrant
Guardant Health announced on September 4, 2026 that the U.S. Food and Drug Administration has approved its Guardant360 CDx blood test as a companion diagnostic for Etcamah (camizestrant), AstraZeneca’s oral selective estrogen receptor degrader, in advanced breast cancer. The FDA…
Tempus Clears Third FDA Cardiac Algorithm: Pulmonary Hypertension ECG Test
Tempus AI has received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-PH, an AI-enabled software device that reads standard 12-lead electrocardiograms for signs associated with pulmonary hypertension — the third FDA-cleared algorithm in the company’s cardiovascular…
